ClinicalTrials.gg
RecruitingNCT06925243Updated Apr 22, 2025

Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

A Phase 3 interventional study of Neoadjuvant apatinib combined with sintilimab and perioperative SOX and Neoadjuvant sintilimab combined with perioperative SOX in Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy and Adjuvant Chemotherapy, sponsored by Zuoyi Jiao. Recruiting at 4 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-22.

Sponsored by Zuoyi Jiao · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
682
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies testing apatinib in Stomach Neoplasms — 14 open to participants now, 15 under way, 4 of them phase 3. apatinib · Stomach Neoplasms.

Planned enrollment
Largest of 57
682 · median 47
Started
2025
with 2 others
Phase 3
9 of 57
4 open now
Primary completion
2027-12
later than 10 of 14 live
Registered
53rd of 57
by date

Among the 57 studies testing apatinib in Stomach Neoplasms, this one has the largest planned enrollment, is one of 3 that started in 2025, is one of 9 in phase 3, reaches primary completion later than 10 of the 14 other live ones, and was the 53rd registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

14 of the 57 studies testing apatinib in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About apatinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing apatinib in Stomach Neoplasms, or all of them as a file.
02

Study summary

This study aims to compare the efficacy and safety of neoadjuvant apatinib combined with sintilimab and perioperative SOX chemotherapy versus neoadjuvant sintilimab combined with perioperative SOX chemotherapy in locally advanced intestinal-type gastric cancer/gastroesophageal junction adenocarcinoma. The primary questions include:

  1. Whether the complete remission rate (pCR) of the apatinib combined with sintilimab and SOX regimen is higher than that of the sintilimab combined with SOX regimen.
  2. The safety of the apatinib combined with sintilimab and SOX regimen.

Participants will be divided into:

  1. Experimental Group: Participants will receive an intravenous injection of sintilimab (200 mg) combined with the SOX regimen (oxaliplatin 130 mg/m² and S-1, with the initial dose determined based on body surface area). Additionally, apatinib (250 mg) will be administered orally once daily during the first three neoadjuvant cycles.
  2. Control Group: Participants will receive treatment with the sintilimab combined with the SOX regimen.

This treatment will be administered for three to four cycles prior to surgery, followed by radical surgery, including D2 or D2+ lymph node dissection. Surgery is scheduled four weeks after the last neoadjuvant therapy (NAT) cycle. Within 3 to 6 weeks post-surgery, patients will begin adjuvant SOX chemotherapy. Postoperative patients will receive four cycles of adjuvant SOX chemotherapy, administered every three weeks.

03

Conditions studied

  • Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])
  • Neoadjuvant Therapy
  • Adjuvant Chemotherapy
  • pCR Rate
  • MPR
  • ORR,OS,PFS

Browse trials for

Keywords

  • apatinib
  • sintilimab
  • SOX
  • Neoadjuvant therapy
  • gastric cancer
  • intestinal type
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Type of Participant and Disease Characteristics

    1. Patients must have a confirmed diagnosis of negative tumor and intestinal type gastric or gastroesophageal junction adenocarcinoma according to Lauren's histological subtypes.
    2. Patients must have previously untreated locally advanced gastric or gastroesophageal junction adenocarcinoma (stage cT2 to cT4), with lymph nodes ranging from N0 to N3 and no evidence of disease (M0).
    3. Patients with Siewert type 2 or 3 tumors are eligible. Enrollment of participants with Siewert type 1 tumors will be limited to those for whom the planned treatment is perioperative chemotherapy and resection.
  2. Demographics

    1. Male or female subjects must be between the ages of ≥ 18 and ≤ 75 years at the time of signing the .
    2. Expected Survival: The expected survival time must be ≥ 12 weeks.
    3. Performance Status: Subjects must have an performance status of 0 or 1.
    4. Male : Non-sterilized male subjects who are sexually active with a female partner of must use an effective method of contraception from Day 1 through 120 days after receipt of the final dose of the product. It is strongly recommended for the female partner of a male subject to also use an effective method of contraception throughout this period.
    5. Female subjects of childbearing potential must be willing to use adequate contraception methods throughout the study and for 120 days after the last dose of the study drug. The decision to discontinue contraception after this time point should be discussed with the attending physician. Periodic abstinence, contraceptive rhythm methods, and withdrawal are not acceptable forms of contraception.

      • Females of childbearing potential are defined as those who are not surgically sterile (e.g., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or (defined as 12 months with no menses without an alternative medical cause).
      • Highly effective contraception methods, resulting in a low failure rate (i.e., less than 1% per year) when used consistently and correctly, are required. Acceptable methods include a combination of a hormonal method (e.g., contraceptive pill) and a barrier method (e.g., male condom plus spermicide) to prevent pregnancy.
      • Barrier methods include male condom plus spermicide, copper T intrauterine device, and levonorgestrel-releasing intrauterine system.

    ii.Hormonal methods include implants, hormone injection, combined pill, minipill, and patch.

    • If a female subject becomes pregnant or suspects pregnancy during her participation in the study or her partner's participation, she must promptly inform her treating physician.
  3. Organ Function

    1. Blood Routine (no blood transfusion within 14 days): WBC ≥ 3.0 × 10\^9/L; ≥ 1.5 × 10\^9/L; ≥ 100 × 10\^9/L; HGB ≥ 80 g/L.
    2. Hepatic Function: Total (TBIL) ≤ 1.5 × , or direct bilirubin ≤ ULN for those with total bilirubin levels 1.5 × ULN and /AST levels ≤ 2.5 × ULN.
    3. Renal Function: Creatinine (Cr) ≤ 1.5 × ULN or (CrCl) ≥ 60 mL/min for those with Cr > 1.5 × ULN.
    4. Coagulation Function: ≤ 1.5 × ULN, APTT ≤ 1.5 × ULN.
    5. Cardiac Function: Cardiac function will be assessed using and color Doppler ultrasound, and subjects must have had no myocardial infarction within the last six months. Hypertension and other coronary heart diseases must be controllable.

      • Females of childbearing potential are defined as those who are not surgically sterile (e.g., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause).
      • Highly effective contraception methods, resulting in a low failure rate (i.e., less than 1% per year) when used consistently and correctly, are required. Acceptable methods include a combination of a hormonal method (e.g., contraceptive pill) and a barrier method (e.g., male condom plus spermicide) to prevent pregnancy.
      • Barrier methods include male condom plus spermicide, copper T intrauterine device, and levonorgestrel-releasing intrauterine system.

    iv.Hormonal methods include implants, hormone injection, combined pill, minipill, and patch.

    • If a female subject becomes pregnant or suspects pregnancy during her participation in the study or her partner's participation, she must promptly inform her treating physician.
  4. Informed Consent All subjects must provide written informed consent to participate in the study.
  5. Other Inclusions

    1. Prior Treatment: Patients must not have previously received any anti-tumor treatments, including radiotherapy, chemotherapy, targeted therapy, or immunotherapy.
    2. Plan to proceed to surgery following pre-operative chemotherapy based on standard staging studies per local practice.

Be willing to provide tissue and blood sample from a tumor lesion at baseline and at time of surgery

Exclusion criteria

Exclusion Criteria:

  1. Medical Conditions

    1. Has a history of (non-infectious) pneumonitis that required or has current pneumonitis.
    2. Has a known additional that is progressing or has required active treatment within the past 5 years (except for cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, or carcinoma in situ that has undergone potentially curative therapy).
    3. Has an active infection requiring systemic therapy.
    4. Has an active disease that has required systemic treatment in the past 2 years. (NOTE: Subjects with vitiligo, alopecia, Grave's disease, Type I diabetes mellitus, hypothyroidism (e.g., following Hashimoto's syndrome) only requiring hormone replacement on a stable dose (without adjustment in the first 4 weeks of study treatment), psoriasis or eczema not requiring systemic treatment (within the past 2 years), or conditions not expected to recur in the absence of an external trigger are not excluded.)
    5. Has any complications requiring systemic treatment with corticosteroids such as prednisone (> 10mg/day) or other medications within 14 days prior to the first administration. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is allowed.
    6. History of primary immunodeficiency.
    7. Has received a or other immune-activating anti-tumor drugs (such as interferon, interleukin, thymosin, or immunotherapy) within 30 days prior to the first dose of study treatment.
    8. Has a known history of active tuberculosis.
    9. Known history of allogeneic organ transplantation and hematopoietic stem cell transplantation.
    10. Has a known severe allergy or to sintilimab or apatinib or any of the study chemotherapy agents and/or to any of their .
    11. Presence of any of the following cardiovascular and cerebrovascular diseases or cardiovascular and cerebrovascular risk factors:

      • Grade II or higher myocardial ischemia or myocardial infarction, poorly controlled arrhythmia (including ≥ 480 ms), grade III or IV cardiac insufficiency, or (LVEF) \< 50.0% as determined by ultrasonic cardiography.
      • Cerebrovascular accident, , or other arteriovenous thrombotic, embolic, or ischemic events.
  2. Prior/Concomitant Therapy

    1. Subjects who have already enrolled in another clinical study, unless it is an observational, non-interventional clinical study, or they are in the follow-up period for an interventional study.
    2. Subjects who have received any systemic or curative anti-tumor therapy, including radiotherapy, chemotherapy, targeted therapy.
    3. Subjects who have previously received any , anti-PD-L1 antibody, or any other antibody or drug therapy targeting T-cell co-stimulation or checkpoint pathway, e.g. ICOS or agonists (e.g., 0, CD137, GITR, and OX40, etc.).
  3. Other exclusion criteria

    1. Confirmed positive tumor will be excluded.
    2. Patients could not provide tumor samples and blood samples.
    3. Pregnant or lactating patients, as well as patients with who plan to be pregnant within 5 months after the study; Women of childbearing should receive a blood pregnancy test within 7 days before the study.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
682 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant apatinib combined with sintilimab and perioperative SOX group

    Participants will receive an intravenous injection of sintilimab (200 mg) combined with the SOX regimen (oxaliplatin 130 mg/m² and S-1, with the initial dose determined based on body surface area). Additionally, apatinib (250 mg) will be administered orally once daily during the first three neoadjuvant cycles. This treatment will be administered for three to four cycles prior to surgery, followed by radical surgery, including D2 or D2+ lymph node dissection. Within 3 to 6 weeks post-surgery, patients will begin adjuvant SOX chemotherapy. Postoperative patients will receive four cycles of adjuvant SOX chemotherapy, administered every three weeks.

    Drug: Neoadjuvant apatinib combined with sintilimab and perioperative SOX

  • Active comparator
    Neoadjuvant sintilimab combined with perioperative SOX group

    Participants will receive an intravenous injection of sintilimab (200 mg) combined with the SOX regimen (oxaliplatin 130 mg/m² and S-1, with the initial dose determined based on body surface area). This treatment will be administered for three to four cycles prior to surgery, followed by radical surgery, including D2 or D2+ lymph node dissection. Within 3 to 6 weeks post-surgery, patients will begin adjuvant SOX chemotherapy. Postoperative patients will receive four cycles of adjuvant SOX chemotherapy, administered every three weeks.

    Drug: Neoadjuvant sintilimab combined with perioperative SOX

Interventions

  • DrugNeoadjuvant apatinib combined with sintilimab and perioperative SOX

    Drug pages: ApatinibStudies of ApatinibApatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · SintilimabStudies of SintilimabSintilimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sintilimab: 200mg, iv, day 1 Oxaliplatin: 130 mg/m², iv, day 1 S-1: 40-60 mg/m², po, day 1-14 (BSA \< 1.25 m², 40 mg bid, 1.25 m² ≤ BSA \< 1.5 m², 50 mg bid, BSA ≥ 1.5 m², 60 mg bid) Apatinib: 250mg, po, day1-21, for 3 cycles preoperatively

  • DrugNeoadjuvant sintilimab combined with perioperative SOX

    Drug page: SintilimabStudies of SintilimabSintilimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sintilimab: 200mg, iv, day 1 Oxaliplatin: 130 mg/m², iv, day 1 S-1: 40-60 mg/m², po, day 1-14 (BSA \< 1.25 m², 40 mg bid, 1.25 m² ≤ BSA \< 1.5 m², 50 mg bid, BSA ≥ 1.5 m², 60 mg bid)

06

What researchers measure

Primary outcomes

  1. Pathological complete response (pCR) rate

    Pathological Complete Response rate (pCR) refers to the proportion of cases in which no active cancer cells are detected in the surgically resected tumor tissue after neoadjuvant therapy, as assessed using the Becker TRG grading system.

    Time frame: Enrollment to surgical treatment takes about 4 months.

Secondary outcomes

  1. Major pathological response (MPR) rate

    Major Pathological Response (MPR) rate refers to the proportion of patients who, after receiving neoadjuvant therapy, are assessed using the Becker TRG grading system and have less than 10% residual viable cancer cells in the surgically resected tumor tissue.

    Time frame: Enrollment to surgical treatment takes about 4 months.

  2. Objective response rate (ORR)

    The Objective Response Rate (ORR) is a widely used efficacy measure in clinical trials, especially in oncology, to assess the objective changes in tumors in response to treatment. It represents the proportion of patients whose tumors have achieved either a Complete Response (CR) or a Partial Response (PR). The assessment of ORR is typically based on the internationally standardized criteria for evaluating solid tumor responses, known as RECIST v1.1 (Response Evaluation Criteria in Solid Tumors, version 1.1).

    Time frame: From enrollment to preoperative imaging assessment, it takes approximately 4 months.

  3. 3-year survival rate (3-year OS rate)

    The 3-year survival rate (3-year OS rate) is the percentage of patients who survive 3 years after enrollment.

    Time frame: From the point of enrollment to the end of the 3-year follow-up period.

  4. Adverse Event

    For the classification and grading of Adverse Events (AEs), the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 is generally used as the standard.

    Time frame: From enrollment to the completion or discontinuation of treatment, an estimated duration of eight months is expected.

  5. Disease control rate (DCR)

    DCR is the percentage of patients with measurable disease at baseline who experience CR, PR, or SD, as determined by BICR using RECIST v1.1 guidelines.

    Time frame: From enrollment to preoperative imaging assessment, it takes approximately 4 months.

  6. 3-year event-free survival rate (3-year EFS rate).

    3-year EFS rate is defined as the proportion of patients who remain free from disease recurrence, progression, or death over a three-year period, without experiencing any predefined adverse events.

    Time frame: From the point of enrollment to the end of the 3-year follow-up period.

  7. R0 resection rate

    The R0 resection rate is defined as the proportion of patients in whom no cancer cells are detected at the surgical margins under microscopic examination, indicating complete removal of the tumor with no visible residual cancer, both macroscopically and microscopically.

    Time frame: Enrollment to surgical treatment takes about 4 months.

  8. Downstaging rates of T, N, TNM stages.

    The tumor downstage rate represents the percentage of patients whose overall ypTNM, T, or N stage has decreased from their baseline cTNM, cT, or cN stage. Tumor staging was assessed using baseline cTNM and postoperative ypTNM evaluations according to the 8th edition of the AJCC Gastric Cancer Staging Manual.

    Time frame: Enrollment to preoperative imaging assessment takes about 4 months.

  9. Surgery-related complications

    Surgery-related complications are defined as any complications occurring within 30 days following surgery, classified according to the Clavien-Dindo Classification of Surgical Complications. These complications include, but are not limited to, vomiting, fever, incision infection, post-operative pneumonia, anastomotic hemorrhage or leakage, chylous leakage, pneumonia, intestinal obstruction, and other related issues.

    Time frame: Enrollment to surgical treatment takes about 4 months.

  10. Programmed death-ligand 1 combined positive score (PD-L1 CPS)

    PD-L1 expression acts as a predictive biomarker for assessing treatment efficacy, encompassing metrics such as the pathologic complete response rate (pCR rate), major pathologic response rate (MPR rate), and both the 3-year overall survival rate (OS rate) and 3-year Event-Free Survival (EFS) rate.

    Time frame: After enrollment, the measurements were completed.

  11. Microsatellite instability (MSI) status

    Microsatellite instability status acts as a predictive biomarker for assessing treatment efficacy, encompassing metrics such as the pathologic complete response rate (pCR rate), major pathologic response rate (MPR rate), and both the 3-year overall survival rate (OS rate) and 3-year Event-Free Survival (EFS) rate.

    Time frame: After enrollment, the measurements were completed.

  12. The ratio of NG2+/CD31

    The ratio of NG2+/CD31 acts as a predictive biomarker for assessing treatment efficacy, encompassing metrics such as the pathologic complete response rate (pCR rate), major pathologic response rate (MPR rate), and both the 3-year overall survival rate (OS rate) and 3-year Event-Free Survival (EFS) rate.

    Time frame: Enrollment to surgical treatment takes about 4 months.

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2027, 32 months after the start.

Of 73 non-industry phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 144. This study's planned 32 months is below that.

Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2025
First posted
Apr 13, 2025
StartActual
Apr 15, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2030
Last update
Apr 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06925243
Lead sponsor
Zuoyi Jiao
Responsible party
Zuoyi Jiao (Medical Professor, Lanzhou University Second Hospital) — Sponsor-investigator
First posted
Apr 13, 2025
Start date
Apr 15, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Apr 22, 2025

Study contacts

Bo Long
Contact
longbo_107@163.com
+86 130 0878 1208

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Apatinib · Sintilimab

Start the discussion